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SUMMARY – Lewy body dementia is a progressive neurodegenerative disease and is considered 
to be the second most common cause of dementia in the elderly. Because of the complexity of clinical 
presentation, it is often misdiagnosed and mistaken for other dementias, which may result in admin-
istering inappropriate therapy, and thus worsening of the patient condition. We reviewed a case of a 
71-year-old patient whose clinical presentation gradually occurred with complex visual hallucinations, 
atypical extrapyramidal motor symptoms, fluctuating cognitive impairments with delirious episodes, 
and oscillating syncope. Depressive mood, impaired daily functioning and sensitivity to antipsychotics 
were also noted. Extensive diagnostic workup was performed with neuropsychological testing and use 
of single-photon emission computerized tomography. Considering the clinical presentation and diag-
nostic procedures performed, the diagnosis of Lewy body dementia was set and pharmacotherapy was 
revised. We discuss the importance of taking overall clinical presentation and diagnostic treatment in 
consideration and applying appropriate therapy to slow down the progression of the disease and exac-
erbation of the patient’s psychological functions.
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Introduction
Lewy body dementia (LBD) is a progressive neu-
rodegenerative disease that is considered to be the sec-
ond most common cause of dementia after Alzheim-
er’s disease (AD)1,2. Usually, it is clinically and patho-
logically overlapping with Parkinson’s disease demen-
tia (PDD) or with AD, making it difficult to identify 
and differentiate in a timely manner3,4. The disease 
starts gradually, usually in the seventh decade, it is 
twice as common in men and can be initially presented 
with dementia or parkinsonism, although patients de-
velop both clinical pictures over time5. LBD is charac-
terized by cognitive fluctuations, behavioral REM 
sleep disturbance, early occurrence of visual hallucina-
tions, and less frequently, by auditory hallucinations or 
delusions1. Parkinsonism in LBD differs somewhat 
from that in Parkinson’s disease, but due to nonspeci-
ficity, LBD is diagnosed when cognitive impairment 
precedes parkinsonism or occurs within a year of the 
appearance of extrapyramidal symptoms (‘one-year 
rule’)3. In addition, significant autonomic dysfunction 
is present in more than half of the patients6, with fre-
quent comorbid anxiety and depression7. Among other 
things, pronounced sensitivity to antipsychotics, espe-
cially dopamine antagonists, is clinically very impor-
tant in recognizing LBD8.
Although the diagnosis of LBD can be confirmed 
with certainty only by autopsy of brain tissue, apart 
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from basic clinical features, differentiation of the diag-
nosis is possible using magnetic resonance imaging 
(MRI) and single-photon emission computerized to-
mography (SPECT), i.e., a finding of temporoparietal 
and occipital hypoperfusion with reduced uptake of 
the striatal dopamine transporter3.
In this paper, we review a case of a man whose clin-
ical presentation, hypersensitivity to antipsychotic 
therapy and diagnostic findings led us to suspect LBD. 
Our aim was to show the complexity of diagnosing 
LBD due to nonspecificity of various symptoms, which 
may result in the administration of inappropriate ther-
apy and deterioration of clinical presentation, and thus 
of the patient condition.
Case Report
A 71-year-old patient, a retired sailor, married, fa-
ther to three children, was admitted to the hospital for 
diagnostic check-up and treatment of organic halluci-
nosis and mildly manifested extrapyramidal symp-
toms. He was unburdened with neuropsychiatric he-
redity. The patient described extrapyramidal disorders 
as initial symptoms, which had begun to appear two 
years after retirement (fifteen years before). At first, he 
was treated with pramipexole dihydrochloride mono-
hydrate. Visual hallucinations then started to appear 
and every day he saw a person he knew but it was not 
real. Parkinson’s disease was diagnosed based on the 
persistence of extrapyramidal symptoms and was 
treated with a combination of levodopa and carbidopa. 
It resulted in intensified visual hallucinations, and the 
patient described it as seeing the crew and ships. 
Shortly before hospitalization, the patient was exam-
ined at a psychiatric outpatient clinic and was diag-
nosed with organic hallucinosis and a depressive epi-
sode. Escitalopram and olanzapine were introduced in 
therapy but the patient did not adhere to treatment 
recommendations. In the last two years, the patient ex-
perienced hypotensive episodes and syncope that led 
to the diagnosis of a cervical syndrome. At the same 
time, the patient experienced deterioration of daily 
functioning with a marked decline in decision making. 
Previously, he was treated for syphilis and suffered 
from asthma and gout. During the examination, he 
complained of frequent urination and constipation. 
He denied taking any psychoactive substances.
On the day of hospital admission, the patient was 
occasionally disoriented, he responded with short la-
tency, along with psychomotor slowing with notice-
able choreiform movements of the body, predominant-
ly of the head, torso and arms. Also, cogwheeling effect 
and lead-pipe resistance were mildly indicated. He ap-
peared to be hypothymic with weak affective modula-
tion and pronounced intrapsychic tension. His thought 
flow was mildly slowed without any delusions in the 
thought content. He confirmed complex visual hallu-
cinations which he described in detail with affective 
engagement. In the domain of personality, he seemed 
inclined to suppression and projection with occasion-
ally reduced tolerance to external frustration. The pa-
tient’s cognitive functions fluctuated throughout the 
day, primarily with impairment of executive functions 
(positive Luria’s test).
Neurological testing revealed dysarthria, bradykine-
sia, hypomimia and elevated muscle tone of extrapyra-
midal type in all extremities, without loss of sensation. 
In Romberg’s position, there was latero- and retropul-
sion, while walking was characterized by smaller steps.
Routine laboratory check-up revealed no signifi-
cant deviations. Brain CT, which was performed due 
to frequent oscillations of consciousness and syncope, 
excluded acute neurological events, as well as any sort 
of an expansion process. Brain MRI showed diffuse 
atrophic changes of the brain with widening of the 
subarachnoid fluid space and brain sulci in frontopari-
etal and temporo-occipital region and atrophic chang-
es of the cerebellum with expanded pericerebellar fluid 
spaces. There was absence of the representation of both 
putamina and the left nucleus caudatus, while the ac-
cumulation in the right nucleus caudatus was relatively 
maintained on the SPECT scan with 123-I ioflupane 
(Fig. 1). Basal brain activity was elevated along with 
severe functional impairment of the striatal dopamine 
system. Serologic testing excluded HIV dementia 
while reactive quantitative TPHA test for syphilis was 
positive. However, due to history data on previously 
treated syphilis, differential diagnosis of neurosyphilis 
was excluded. Neurologically determined anosmia was 
differentiated as a condition that occurred due to post-
infectious neuritis along with subsequent permanent 
damage to the olfactory nerve. Neuropsychological 
testing using the instruments of clinical interview, WB 
II Verbal Part, WB Memory Scales, FAS and Rey 
Complex Figure Test revealed impaired verbal fluency, 
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decreased memory and learning ability, reduced visual-
motor abilities, and concentration disturbances.
Considering the diagnostic workup performed 
(clinical signs and neuroradiological confirmation), the 
diagnosis of LBD was made and pharmacotherapy was 
revised. During hospitalization, pramipexole was ex-
cluded from therapy due to worsening of visual halluci-
nations, while levodopa/carbidopa was continued at a 
dose of 250/25 mg TID. Rivastigmine was also intro-
duced at a dose of 3 mg daily and divided into morning 
and evening applications as an acetylcholinesterase in-
hibitor recommended for the treatment of this type of 
dementia. Due to complex hallucinatory experiences 
and consequential affective engagement, clozapine was 
administered as an evening dose of 25 mg. Visual hal-
lucinations then diminished and ceased, while the ex-
trapyramidal symptoms were less pronounced, as well as 
cognitive fluctuations, with absence of delirium episodes 
and normalization of circadian rhythm.
Discussion and Conclusion
The variety of clinical presentation in the reviewed 
patient manifested as fluctuating cognitive impairments 
primarily in executive functioning with fluctuating de-
lirious episodes and daily drowsiness, complex visual 
hallucinations, and atypical extrapyramidal motor 
symptoms. Episodes of oscillating syncope were pres-
ent, as well as depressive mood and sensitivity to anti-
psychotics. A similar clinical state is described by 
Wearne et al.9. Based on the clinical state and diagnostic 
workup performed, LBD was suspected, with difficult 
differentiation from other dementias, especially AD and 
PDD, as well as their possible combinations10,11.
It is considered that the main feature of LBD is 
fluctuation of cognitive functions, which can be ob-
served in most patients12. However, there are difficul-
ties in consistent assessment of their presence3,13. Neu-
ropsychological assessment of the presented patient 
revealed reduced memory capacity and learning ability, 
with reduced visual motor abilities and concentration 
disturbances, which is consistent with the data avail-
able14. However, although memory impairment occurs 
at an earlier stage of both disorders, the pattern of neu-
ropsychological deficits in LBD differs from that in 
AD in terms of less pronounced memory impairment 
and more serious impairment of visual spatial orienta-
tion, attention, and executive functions13,15.
Furthermore, in our patient, as well as in around 
half of the patients diagnosed with LBD, well-formed 
visual hallucinations are present, which also are the 
most frequent psychiatric symptom of LBD. They may 
be accompanied by auditory hallucinations, delusions, 
anxiety, and behavioral disturbances, all of which dis-
tinguish this disease from dementia of another etiolo-
gy, or from delirium induced by external causes16,17. The 
presence of visual hallucinations and cognitive impair-
ment is associated with acetylcholinesterase deficiency, 
which is more pronounced in LBD than in AD18, and 
a correlation of visual hallucinations with the distribu-
tion of Lewy bodies in temporal lobes was also noted19.
The above-mentioned extrapyramidal symptoms in 
LBD are present in 25% to 50% of patients, and they 
are similar to those in Parkinson’s disease with more 
pronounced postural instability, reduced facial expres-
sion, and less pronounced tremor, but with regard to 
clinical similarity between LBD and PDD, they often 
are differentiated by the use of already mentioned 
‘one-year rule’3,20.
Depressive symptoms can be present in 33% to 50% 
of LBD patients, which was the case in our patient, 
which makes a greater percentage in relation to AD and 
similar percentage in relation to PDD17,21,22. Retrospec-
tive case-control studies indicate that the occurrence of 
depression or delirium before the diagnosis of dementia 
is more common in LBD than in AD7.
Spread of LBD related pathology to the brainstem 
and autonomic nervous system leads to orthostatic hy-
Fig. 1. SPECT scan with 123-I ioflupane showing 
elevated basal brain activity, along with severe functional 
impairment of the striatal dopamine system.
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potension and/or carotid sinus hypersensitivity, which 
consequently leads to syncope episodes that are more 
common in LBD than in AD6. Other symptoms such 
as constipation, REM sleep disturbances with daily 
drowsiness and restlessness during the night, hypos-
mia and postural vertigo appear several years prior to 
memory disorder in LBD23,24. Untimely urinary incon-
tinence was observed in LBD, unlike AD, and it re-
flects an autonomic nervous system disorder25. Symp-
toms of autonomic dysfunction were present in our 
patient, which is consistent with the data reported by 
Horimoto et al., who established that all subjects ex-
hibited some of the symptoms of autonomic dysfunc-
tion, and 62% experienced symptoms of severe auto-
nomic dysfunction6.
In the available literature, there are abundant data 
on difficulties in differentiating among different types 
of dementia, LBD not being an exception. LBD could 
be misdiagnosed as PDD because of clinical manifes-
tations26,27, as in the case presented, and often as AD26 
or frontotemporal dementia28. Although a specific bio-
marker is still not available to confirm the LBD diag-
nosis, MRI findings in those involved, as in our pa-
tient, show a relatively preserved medial temporal lobe 
cortex with global cortical atrophy in comparison to 
patients with AD29, while structural changes shown by 
MRI in LBD compared to PDD are relatively identi-
cal30. Furthermore, SPECT scans can be used to evalu-
ate the integrity of dopaminergic nigrostriatal neurons, 
as well as to distinguish LBD from other forms of de-
mentia. Namely, a possible indicative biomarker for 
LBD is a reduced intake of dopamine transporter into 
basal ganglia31, as confirmed in the case presented.
Regarding treatment, cholinesterase inhibitors may 
be used due to the already mentioned acetylcholine 
deficiency in LBD32-34, as confirmed in a case study35. 
They are effective in treating cognitive and behavioral 
symptoms, as well as visual hallucinations. We opted to 
use rivastigmine which improved the patient’s condi-
tion. It is stated that more than 50% of patients have a 
strong reaction to antipsychotics in terms of hypersen-
sitivity8, especially with typical antipsychotics, which 
also have a higher risk of parkinsonism, as well as a 
higher potency of atypical ones, such as olanzapine 
and risperidone36. But, due to complex hallucinatory 
experiences in our patient, clozapine was introduced to 
treatment, a drug with a proven positive effect on 
PDD37. However, quetiapine is the recommended 
choice for antipsychotic treatment in LBD because of 
the more favorable side effect profile, although evi-
dence for its efficacy is limited38. Also, a combination 
of levodopa/carbidopa was introduced for the purpose 
of reducing motor disturbances, which is consistent 
with the recommendations for treating LBD39.
Lewy body dementia should be taken in consider-
ation whenever there are well-formed visual hallucina-
tions, cognition fluctuations, parkinsonism or neuro-
psychological deficits at clinical presentation. Due to 
the differential diagnostic complexity and sensitivity 
to psychopharmacotherapy, further research is required 
to minimize deterioration of mental functions and 
daily functioning and to slow down the progression of 
the disease.
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Sažetak
ENIGMA DEMENCIJE LEWYJEVIH TJELEŠACA: PRIKAZ SLUČAJA
I. Orlović, M. Bartolović, K. Marušić, D. Vlahović, I. Šiško Markoš, D. Karlović i V. Peitl
Demencija Lewyjevih tjelešaca je neurodegenerativna bolest i drugi najčešći uzročnik demencije u starijih osoba. Zbog 
složenosti kliničke slike često se pogrešno dijagnosticira i nerijetko zamijeni s drugim demencijama, što dovodi do primjene 
neodgovarajuće terapije, a time i pogoršanja stanja bolesnika. Prikazujemo slučaj bolesnika u dobi od 71 godine kod kojega 
se klinička slika postupno prezentirala složenim vizualnim halucinacijama, atipičnim ekstrapiramidnim motoričkim ispadi-
ma, fluktuirajućim kognitivnim smetnjama uz delirantne epizode i oscilirajuće sinkope. Kod bolesnika je zabilježeno depre-
sivno raspoloženje, narušeno svakodnevno funkcioniranje i osjetljivost na psihofarmake. Provedena je opširna dijagnostička 
obrada uz neuropsihologijsko testiranje i primjenu jednofotonske emisijske tomografije. Na temelju kliničke slike i diferen-
cijalno dijagnostičke obrade posumnjalo se na demenciju Lewyjevih tjelešaca. Raspravljamo o važnosti uzimanja u obzir 
cjelokupne kliničke slike i dijagnostičke obrade te primjeni odgovarajućeg liječenja u svrhu prevencije progresije bolesti i 
pogoršanja psihičkih funkcija bolesnika.
Ključne riječi: Demencija Lewyjevih tjelešaca; Kognitivno oštećenje; Halucinacije; Parkinsonov sindrom; Inhibitori kolineste-
raze; Demencija
